Interesting integration of ctdna directed therapy in NSCLC
✅️ baseline non-detectable ctDNA -> good prognosis, might be an option for Osimertinib mono
✅️ if without ctDNA clearance after 3-4 weeks -> better median PFS if chemo is addred to osi mono
#ESMO26
18 浏览 · 0 赞 · 0 转发 · 0 回复
FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)
https://esmocongress.esmo.orgPACE-LUNG: A multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line
https://esmocongress.esmo.org来源：Kenn Samala · x.com